Evercore ISI analyst Vedvati Shrotre reiterated a Buy rating on Nova (NVMI – Research Report) on March 14 and set a price target of $300.00.

Evercore ISI analyst David Palmer maintained a Buy rating on Darden Restaurants (DRI – Research Report) on March 14 and set a price target of ...

Reinsurance Group of America (NYSE:RGA – Get Free Report) had its target price dropped by Evercore ISI from $280.00 to ...

The new price target of $99 takes into account the potential of CRISPR Therapeutics' in vivo programs, CTX320 and CTX310. Evercore ISI has assigned a probability of success (POS) of 10% and 5% to ...

CenterPoint upgraded at Evercore ISI, seeing the stock returning to its pre-2024 10%-plus premium vs. 5% currently with visibility to a positive resolution of the Texas electric rate case.

Ingram Micro (NYSE:INGM – Free Report) had its target price cut by Evercore ISI from $27.00 to $26.00 in a research report ...

CRISPR Therapeutics (CRSP) shares jump after Evercore ISI upgraded the stock to Outperform from In Line. Julie Hyman and Josh Schafer examine what the analysts say about the biotech company on ...

Investing.com -- Evercore ISI added Wendy’s Co to its Tactical Outperform list ahead of the company’s investor day on March 6, citing discounted valuation, a potential industry turnaround ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (BRSE:1CG) from In-Line to Outperform. There are 577 funds or institutions reporting ...

On Friday, Evercore ISI analyst Stephen Richardson raised the rating for Canadian Natural Resources Limited (TSX:CNQ:CN) (NYSE: CNQ) from In Line to Outperform, while maintaining the price target ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. As of January 28, 2025, the average one-year ...